Marc R. Larochelle MD, MPH

Associate Professor, General Internal Medicine

801 Massachusetts Ave | (617) 414-7399
Marc Larochelle
Sections

General Internal Medicine

Centers

Clinical Addiction Research and Education Unit

Biography

Marc Larochelle is a general internist and clinical investigator specializing in addiction medicine at BMC and an assistant professor of medicine at BUSM. Larochelle's clinical and research interests focus on the safety of opioid prescribing and the recognition and treatment of opioid use disorders. As a health services researcher, Larochelle aims to leverage insights from large data sources and translate the findings into interventions that improve the quality and value of health care delivered. His special interests are Primary Care and Addiction Medicine.

Education

Medicine-Internal, MD, University of Pittsburgh School of Medicine

Clinical Evaluation/Research, MPH, Harvard School of Public Health

Biomedical Engineering, BSE, Duke University

Publications

Published on 3/22/2024

Christine PJ, Lodi S, Hsu HE, Bovell-Ammon B, Yan S, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz J, Walley AY, Larochelle MR. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024 Mar 22. PMID: 38519819.

Published on 3/4/2024

Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Netw Open. 2024 Mar 04; 7(3):e242732. PMID: 38497959.

Published on 2/3/2024

Bauer C, Hassan GH, Bayly R, Cordes J, Bernson D, Woods C, Li X, Li W, Ackerson LK, Larochelle MR, Stopka TJ. Trends in Fatal Opioid-Related Overdose in American Indian and Alaska Native Communities, 1999-2021. Am J Prev Med. 2024 Jun; 66(6):927-935. PMID: 38311190.

Published on 12/18/2023

McCann NC, LaRochelle MR, Morgan JR. Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort. J Subst Use Addict Treat. 2024 Apr; 159:209281. PMID: 38122988.

Published on 10/13/2023

Tilhou AS, Murray E, Wang J, Linas BP, White L, Samet JH, LaRochelle M. Trends in buprenorphine dosage and days supplied for new treatment episodes for opioid use disorder, 2010-2019. Drug Alcohol Depend. 2023 Nov 01; 252:110981. PMID: 37839942.

Published on 10/6/2023

Christine PJ, Larochelle MR, Lin LA, McBride J, Tipirneni R. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder. JAMA Health Forum. 2023 Oct 06; 4(10):e233549. PMID: 37862034.

Published on 10/2/2023

Hammerslag LR, Mack A, Chandler RK, Fanucchi LC, Feaster DJ, LaRochelle MR, Lofwall MR, Nau M, Villani J, Walsh SL, Westgate PM, Slavova S, Talbert JC. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees. JAMA Netw Open. 2023 Oct 02; 6(10):e2336914. PMID: 37851446.

Published on 8/23/2023

Pustz J, Srinivasan S, Shrestha S, Larochelle MR, Walley AY, Samet JH, Babakhanlou-Chase H, Carpenter JF, Stopka TJ. Applied risk mapping and spatial analysis of address-level decedent data to inform opioid overdose interventions: The Massachusetts HEALing Communities Study. Drug Alcohol Depend. 2023 Oct 01; 251:110947. PMID: 37666091.

Published on 8/17/2023

Scherrer JF, Sullivan MD, LaRochelle MR, Grucza R. Validating opioid use disorder diagnoses in administrative data: a commentary on existing evidence and future directions. Addict Sci Clin Pract. 2023 Aug 17; 18(1):49. PMID: 37592369.

Published on 6/1/2023

Chhatwal J, Mueller PP, Chen Q, Kulkarni N, Adee M, Zarkin G, LaRochelle MR, Knudsen AB, Barbosa C. Estimated Reductions in Opioid Overdose Deaths With Sustainment of Public Health Interventions in 4 US States. JAMA Netw Open. 2023 Jun 01; 6(6):e2314925. PMID: 37294571.

View full list of 96 publications.